Department of Nuclear Medicine, Hospital of Haicang, Xiamen, Fujian, China.
Department of Anesthesiology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China.
Technol Health Care. 2023;31(S1):357-372. doi: 10.3233/THC-236031.
125I BT is an effective radiotherapy for prostate cancer. However, comparison data of GI and GU toxicities between BT, BT + EBRT, and EBRT-alone patient groups is limited.
To define the GI and GU toxicities in prostate cancer to prevent adverse events after treatment.
We searched published studies in PubMed, Cochrane, and Embase databases up to December 31, 2022. The endpoints were the RRs of GI and GU toxicities. Pooled data were assessed using a random-effects model.
Fifteen eligible studies were included into this analysis. LDR-BT had significantly lower RRs than LDR-BT + EBRT for acute GI (2.13; 95% CI, 1.22-3.69; P= 0.007) and late GI toxicities (3.96; 95% CI, 1.23-12.70; P= 0.02). Moreover, EBRT had significantly higher RRs than LDR-BT for acute GU (2.32; 95% CI, 1.29-4.15; P= 0.005) and late GU toxicities (2.38; 95% CI, 1.27-4.44; P= 0.007). HDR-BT had significantly higher RRs for acute GU toxicities than LDR-BT alone (0.30; 95% CI, 0.23-0.40; P< 0.00001).
The results implied that BT with and without EBRT can result in both GI and GU toxicities in patients with prostate cancer, with LDR-BT leading to a poorer urinary function than EBRT.
125I BT 是一种有效的前列腺癌放射治疗方法。然而，BT、BT+EBRT 和 EBRT 单独治疗患者组之间 GI 和 GU 毒性的比较数据有限。
明确前列腺癌的 GI 和 GU 毒性，以预防治疗后不良事件的发生。
我们在 PubMed、Cochrane 和 Embase 数据库中检索截至 2022 年 12 月 31 日已发表的研究。终点是 GI 和 GU 毒性的 RR。使用随机效应模型评估汇总数据。
共有 15 项符合条件的研究纳入本分析。LDR-BT 治疗组与 LDR-BT+EBRT 治疗组相比，急性 GI（2.13；95%CI，1.22-3.69；P=0.007）和晚期 GI 毒性（3.96；95%CI，1.23-12.70；P=0.02）的 RR 显著降低。此外，EBRT 治疗组与 LDR-BT 治疗组相比，急性 GU（2.32；95%CI，1.29-4.15；P=0.005）和晚期 GU 毒性（2.38；95%CI，1.27-4.44；P=0.007）的 RR 显著升高。HDR-BT 治疗组与 LDR-BT 单独治疗组相比，急性 GU 毒性的 RR 更高（0.30；95%CI，0.23-0.40；P<0.00001）。
结果表明，BT 联合或不联合 EBRT 均可导致前列腺癌患者出现 GI 和 GU 毒性，LDR-BT 导致的尿功能比 EBRT 差。
